---
title: "New German expert consensus highlights role for NPWT in mitigating the economic impact of postoperative wound complications"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292155791.md"
description: "Global medical technology company Smith+Nephew (LSE: SN, NYSE: SNN) has released new guidance for the use of single-use negative pressure wound therapy (sNPWT) in closed surgical incisions. Developed by expert clinicians, the consensus-based guidance includes practical clinical practice recommendations specifically tailored for Germany. The guidance has been published in the esteemed journal of surgery Die Chirurgie. Smith+Nephew, a leader in sNPWT and the maker of the PICO™7 sNPWT system, supported the development of this new German consensus."
datetime: "2026-07-09T06:02:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292155791.md)
  - [en](https://longbridge.com/en/news/292155791.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292155791.md)
---

# New German expert consensus highlights role for NPWT in mitigating the economic impact of postoperative wound complications

Global medical technology company Smith+Nephew (LSE: SN, NYSE: SNN) has released new guidance for the use of single-use negative pressure wound therapy (sNPWT) in closed surgical incisions. Developed by expert clinicians, the consensus-based guidance includes practical clinical practice recommendations specifically tailored for Germany. The guidance has been published in the esteemed journal of surgery Die Chirurgie. Smith+Nephew, a leader in sNPWT and the maker of the PICO™7 sNPWT system, supported the development of this new German consensus.

### Related Stocks

- [SNN.US](https://longbridge.com/en/quote/SNN.US.md)

## Related News & Research

- [Smith & Nephew’s Kashyap sells shares worth GBP 101,672 to cover tax on award vesting](https://longbridge.com/en/news/295685894.md)
- [Smith+Nephew to Showcase Growth-Driving Surgical Innovations at June Investor Event](https://longbridge.com/en/news/284201150.md)
- [Amylyx Says Phase 3 Trial of Avexitide For Post-Bariatric Hypoglycemia Met Main Goal](https://longbridge.com/en/news/296218787.md)
- [Amylyx to release Phase 3 LUCIDITY trial topline results for avexitide in post-bariatric hypoglycemia Aug. 18, 2026](https://longbridge.com/en/news/296140552.md)
- [RWJBarnabas’ Clara Maass Medical Center secures ACS Commission on Cancer accreditation](https://longbridge.com/en/news/296135696.md)